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Background and Objective: Statins are one of the most prescribed drugs to treat
atherosclerosis. They inhibit the hepatic HMG-CoA reductase, causing a reduction of
circulating cholesterol and LDL levels. Statins have had undeniable success; however,
the benefits of statin therapy crystallize only if patients adhere to the prescribed treatment,
which is far away from reality since adherence decreases with time with around half
of patients discontinue statin therapy within the first year. The objective of this work
is to; firstly, demonstrate a formal in-silico methodology based on a hybrid, multiscale
mathematical model used to study the effect of statin treatment on atherosclerosis
under different patient scenarios, including cases where the influence of medication
adherence is examined and secondly, to propose a flexible simulation framework that
allows extensions or simplifications, allowing the possibility to design other complex
simulation strategies, both interesting features for software development.
Methods: Different mathematical modeling paradigms are used to present the
relevant dynamic behavior observed in biological/physiological data and clinical trials.
A combination of continuous and discrete event models are coupled to simulate the
pharmacokinetics (PK) of statins, their pharmacodynamic (PD) effect on lipoproteins
levels (e.g., LDL) and relevant inflammatory pathways whilst simultaneously studying the
dynamic effect of flow-related variables on atherosclerosis progression.
Results: Different scenarios were tested showing the impact of: (1) patient variability:
a virtual population shows differences in plaque growth for different individuals could be
as high as 100%; (2) statin effect on atherosclerosis: it is shown how a patient with a
1-year statin treatment will reduce his plaque growth by 2–3% in a 2-year period; (3)
medical adherence: we show that a patient missing 10% of the total number of doses
could increase the plaque growth by∼1% (after 2 years) compared to the same “regular”
patient under a 1-year treatment with statins.
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Conclusions: The results in this paper describe the effect of pharmacological
intervention combined with biological/physiological or behavioral factors in
atherosclerosis progression and treatment in specific patients. It also provides an
exemplar of basic research that can be practically developed into an application
software.
Keywords: atherosclerosis, statins, multiscale modeling, hybrid model, patient adherence,
pharmacokinetics/pharmacodynamics (PKPD), quantitative systems pharmacology (QSP)
INTRODUCTION
Atherosclerosis is a chronic disease that has become a burden
in cardiovascular services being the leading cause of death in
the western world. The clinical manifestation of atherosclerosis
includes coronary artery disease (CAD), cerebrovascular disease
(CVA), and peripheral arterial disease (PAD), having an
incidence of 67% for men and 50% for women after the age
of 40 (Robinson et al., 2009). The process of atherosclerotic
plaque formation is very complex, multifactorial, and systemic.
There is evidence from experimental findings supporting the
fact that hemodynamic stimuli have an influence on physical
properties of the arterial endothelium, e.g., permeability and
cell geometry, likely causing an accumulation of lipoprotein
macromolecules (e.g., Low Density Lipoproteins—LDL) and
atherosclerosis progression. During the early stages of the
disease, after monocytes infiltrate the arterial wall, lipid-laden
macrophages (foam cells) accumulate in the subendothelium,
following an accumulation of fibrous tissue and smooth muscles
cells. The formation of the lesions is promoted by plasma proteins
carrying elevated levels of cholesterol and triglycerides. On top of
this, environmental factors are understood to play a role as well as
genetic makeup (Fox et al., 2003). The framework that surrounds
the atherosclerotic process is bewildering in complexity and
extent. Understanding and managing these combined cause-
effect relationships proves challenging for clinicians, who must
deal with the disease and its consequences every day.
This is a case where integrative, multi-scale, mechanistic,
computational models can offer much needed help. Disease
simulation models can capture complex characteristics and
mechanisms (albeit, simplified) in order to use an in silico
approach for the analysis, exploration, and understanding of
the development of these diseases (Alimohammadi et al., 2016,
2017; Donadoni et al., 2017). These mechanistic, simulation
models offer strong interpretability and understanding of the
underlying processes and their interplay in the development
of the disease. They also offer the possibility to combine
the disease model with more conventional approaches
such as pharmacokinetics-pharmacodynamics (PK-PD) or
physiologically-based pharmacokinetic models (PBPK) to
understand two key aspects of medical treatment: (a) the effect of
drugs on disease progression and (b) to explore diverse scenarios
to analyze the effect of patient adherence.
The objective of this paper is to provide, for the first
time, a detailed description of an integrative, multi-scale model
(or Quantitative Systems Pharmacology—QSP model) used to
(a) understand the effect of statins on the progression of
atherosclerosis and (b) to understand the effect of patient
adherence through multiple (possible) scenarios, all while
describing in detail the formalisms and methodologies involved.
Statins are amongst the most prescribed drugs worldwide and
they are typically prescribed for a lifetime. This is a key issue as
statins have well-known side-effects and relatively recent studies
have also linked statins to other conditions (Shah and Goldfine,
2012). Patient adherence has also been shown to be an issue
(Maningat et al., 2013) since adherence decreases with time and
around half of patients discontinue statin therapy within the first
year. Prescription of statins is being debated as a public health
issue with also, significant implications in the budgets of national
health systems.
The QSPmodel presented in this paper integrates information
from the physiology of the patient, hemodynamics, the dynamics
of immune cells and lipids, and the dynamic effect of statins
(in this particular case, simvastatin), as discussed in Pichardo-
Almarza and Diaz-Zuccarini (2016). The description and use of
this model exemplifies the combination of different modeling
paradigms from a pure modeling point of view whilst also
providing a concrete case study of its potential usability as
an application software in a clinical environment by assessing
the effect of pharmacological intervention combined with
biological/physiological or behavioral factors in atherosclerosis
progression and treatment in specific patients.
The paper is organized as follows: Section Methods presents a
formal description of different mathematical paradigms used to
model the disease (i.e., atherosclerosis) and the effect of the statin
(simvastatin). Section Results: A Case Study presents a case study
with the simulations from the model, showing different case
scenarios based on drug administration, patient variability, and
medication adherence. Finally, Sections Discussion and Model
Validation show the discussion and conclusions of this work.
METHODS
Modeling the Atherosclerotic Process
Themain assumption of the atherosclerosis model proposed here
is that the penetration of LDL into the intima of the vessel is
the main trigger of the disease (Osterud and Bjorklid, 2003),
where it is oxidized by free radicals leading to an inflammatory
response: monocytes adhere to the endothelium, penetrating
into the intima, differentiating then into macrophages (see
Figure 1). Due to a chronic inflammatory response, secretion
of pro-inflammatory cytokines promotes the recruitment of
circulating monocytes, which differentiate to macrophages in
the arterial wall. Foam cells are produced due to the uptake of
Frontiers in Pharmacology | www.frontiersin.org 2 September 2017 | Volume 8 | Article 635
Pichardo-Almarza and Diaz-Zuccarini QSP Modeling and Statin Adherence
oxidized LDL (ox-LDL) by macrophages, which may be removed
by the immune system.
A continuous modeling approach including the mechanisms
described above divides the model in two main parts: a
“biochemical” model describing the LDL dynamics (including
its oxidation) and the immune response (e.g., pro and anti-
inflammatory cytokine effect); and a “mechanical” model
describing the plaque growth and the effect of blood flow
and mechanical stimuli (wall shear stress) on the endothelium
on the evolution of the plaque. In this model, the location
FIGURE 1 | Simplified atherosclerotic process. A plethora of mechanisms at different levels (hemodynamic, cellular, sub-cellular, etc.) are involved in plaque formation.
Please note that this is a “positive feedback loop” with nested/coupled processes. Species concentrations in the lumen and the arterial wall (and the WSS) are affected
by changes in the arterial wall. Arterial hemodynamics will be affected by arterial remodeling and this in turn, will affect the accumulation of lipids inside the arterial wall.
FIGURE 2 | Diagram of the multiscale modeling approach showing how different mathematical approaches are used/needed to study atherosclerosis and its
treatment.
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of atheroscleorotic plaque is associated with low shear stress;
using evidence that suggests the effect of shear stress through
endothelial gene expression or by a process of localized
inflammation (Cheng et al., 2004). Figure 2 shows a simplified
diagram of the processes described by this mathematical model.
For each sub-section, the modeling paradigm used (continuous
model, Markov model, discrete events, etc.) will be detailed.
Hemodynamics and Wall Shear Stress (WSS):
A Continuous Model
The model proposed includes a description of the dynamics of
the blood flow. The continuity (1) and Navier-Stokes equations
(2) are used for the hemodynamics.
∂ρ
∂t
+ ∇ · (ρ U) = 0 (1)
∂ (ρ U)
∂t
= −∇p+∇ · τij + ρg (2)
Where: p= pressure,
∇ · τij = shear stress tensor,
ρ = density,
U = flow velocity.
Transport of molecules from the lumen to the arterial wall can be
significantly enhanced or impeded by local flow conditions near
the wall and are typically characterized by the WSS.
Endothelial Behavior and Membrane-Transport
Model: A Continuous Model
The Kedem Ketchalsky’s equations (Kedem and Katchalsky,
1958) are proposed to model the LDL flux across the
endothelium:
Jv = Lp(1p− σ15) (3)
Js = P01c+ Jv (1− σ) Jvc (4)
Where:
Jv = transmural velocity
Js = LDL flux through the endothelium
Lp = hydraulic conductivity
1p= pressure difference across the endothelial membrane.
15 = osmotic pressure difference across the endothelial
membrane
P0 = diffusive endothelial permeability
1c= solute concentration
c=mean endothelial concentration
σ = reflection coefficient.
Lp incorporates the effect of WSS on cellular processes altering
transendothelial transport (e.g., intercellular junctions; Chang
et al., 2000; Tarbell, 2010). Specific details about howWSS affects
the transport of LDL through the endothelium and how the
hydraulic conductivity is affected by flow-related variables will
not be described here in an effort to be compact; the reader
is kindly referred to previous publications (Alimohamadi et al.,
2015; Alimohammadi et al., 2016, 2017) for reference.
Transport Process Inside the Arterial Wall:
A Continuous Model
Macromolecule transport (e.g., LDL) from the lumen to the
arterial wall as part of the atherosclerosis progression is typically
modeled using a convection-diffusion-reaction (see for example
Di Tomaso et al., 2011; Díaz-Zuccarini et al., 2014):
dLw
dt
= −uw · ∇Lw + DwLw − rwLw (5)
Where:
uw = transmural velocity
Dw = diffusivity of LDL in the wall
rw = reaction rate constant representing LDL oxidation.
Once LDL is inside the arterial wall it will be oxidized by
Reactive Oxygen Species (ROS) triggering an inflammatory
response: (1) monocytes will penetrate from circulation and
will differentiate to macrophages; (2) macrophages will uptake
oxidized LDL to create foam cells that will accumulate as part
of the atherosclerotic plaque. All these additional mechanisms
related to the LDL oxidation and inflammation are implemented
in the integrated multiscale model by using continuous ODEs
equations based on mass conservation laws for each biochemical
species. This part of the model is also affected by WSS values
calculated from the hemodynamic module described above (for
more details about the model, see Pichardo-Almarza et al., 2014).
Modeling Atherosclerotic Plaque Growth: A Discrete
Event
The atherosclerotic plaque volume (i.e., volume of intima
and media layers) is calculated adding the volumes
occupied by the different cells and macromolecules (i.e.,
LDL, monocytes, macrophages, foam cells) inside the
arterial wall.
The formation of the initial stages of the plaque is simulated
assuming the lumen will narrow if the volume occupied by all the
biochemical species in the wall is bigger than the initial volume
of the arterial wall (Figure 3). The amount of foam cells is the key
variable to determine this arterial remodeling.
The approach proposed in this work is based on a discrete
event in order to pass from “Constant Volume” to “Plaque
Growing” in the complete multiscale model.
Modeling the Effect of the Drug Using a
Pharmacokinetic/Pharmacodynamic
(PKPD) Model of Statins: A Continuous
Model
The continuous PKPD model used in this work is based on a
previous published model (Kim et al., 2011). The approach uses a
classical compartmental model to describe the PK of Simvastatin
and its PD effect on lowering LDL in male volunteers.
The PK model consists of a parent/metabolite
(simvastatin/simvastatin acid) model with first-order absorption
and elimination, being a good configuration to fit the PK
data. The PD model describes the effect of simvastatin on
circulating LDL levels using an inhibitory turnover model with
the metabolite (simvastatin acid) as the driver (Figure 4).
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The PKPD model is shown in Figure 4. This model
reproduces the temporal behavior of the drug (simvastatin)
related to its absorption, metabolism, and its pharmacological
effect on hepatic cholesterol production and circulating
LDL. This continuous model describe these mechanisms
mathematically using a set of ordinary differential equations
(ODEs) based on a PKPD model with two standard
compartments (Kim et al., 2011). This effect on LDL is then
translated to the physiological model of the artery that describe
the plaque growth based on different mechanisms related
to LDL transport (and accumulation) and the inflammatory
FIGURE 3 | “Growth” as implemented in the model. The arterial lumen (in
white) would be remodeled as a consequence of volume growth (inner region
of the artery) due to plaque formation and development in time (in yellow).
FIGURE 4 | Diagram of the pharmacokinetics/pharmacodynamics (PKPD)
model (Kim et al., 2011).
response (as described in Section Modeling the Atherosclerotic
Process).
Daily Dose of Statins (Multiple Dosing):
Discrete Events
Using the previous PKPD model is not enough to describe a daily
dose of statins. A multiple dose scheme is by nature a discrete
model where the amount of drug in the circulation increases at
specific times of the day (See Figure 5). Thus, to evaluate the
effect of multiple dosing in the current model, a hybrid approach
is used, where the dose is modeled as a discrete sequence with a
specific amount of drug (modifying the initial conditions of the
drug inside the gut compartment in the PKPD model shown in
the previous section) and predetermined times. Figure 5 shows
an example of the dose sequence mainly depending on the dose
intervals specified by the user.
Evaluating Medication Adherence:
A Markov Chain Model
The previous model of multiple dosing is useful in order
to understand the pharmacokinetics of the drugs and their
dynamic effect on atherosclerosis. However, themain assumption
of the previous model is that the “patient” being modeled
is considered to be adherent to his medication following
implementation of a given dosing regime, i.e., the patient
is taking all his daily doses as prescribed. Lack of patient
adherence when treated with statins is a problem widely
reported in the literature (Maningat et al., 2013). The
computational approach presented here can be used to
understandmore realistic situations wheremedication adherence
in an issue, in which case, a probabilistic model can be
used.
A two stateMarkov chain is proposed to include the variability
on medication adherence in different patients, conditional to the
temporal scheme for drug administration proposed in the model,
i.e., daily dose of Simvastatin mentioned above.
FIGURE 5 | Example time course of how the dose will be administered based
on the Discrete Events. Time(0) corresponds to the initiation (Vrijens et al.,
2012) (time for the first dose).
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FIGURE 6 | (A) Markov Chain: Evaluating Medication Adherence; pt and qnt
are probabilities based on the previous action (i-1). (B) Illustration of how the
dose regime is affected by the Markov Chain.
Two conditional probabilities of taking or not the daily dose
are used to define the two state Markov chain, based on the
patient’s behavior the previous time (see Figure 6).
In this case, probabilities Pt and Qnt are defined as follows:
P(yi = “Taking Drug” | yi−1 =“Taking Drug”)= pt (6)
P(yi = “Not Taking Drug” | yi−1 =“Not Taking Drug”)= qnt
(7)
From which:
P(yi=“Not Taking Drug” | yi−1 =“Taking Drug”)= 1−pt (8)
P(yi = “Taking Drug” | yi−1 =“Not Taking Drug”)= 1−qnt
(9)
Which yields to the Markov transition matrix:
P =
[
pt 1− pt
1− qnt qnt
]
(10)
Implementing the Markov chain described above allows the user
to incorporate into the model the effect of adherence: initiation
and implementation (i.e., the patient following the regime or
missing some doses), which could be used to understand changes
in plaque progression depending on individual behaviors.
Figure 6B shows an illustration of how the dose regime can
be affected when implementing the Markov Chain to study
medication adherence.
FIGURE 7 | Flowchart of the computational algorithm used to simulate the multiscale model. Patient adherence: initiation, implementation and discontinuation defined
as proposed by Vrijens et al. (2012).
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TABLE 1 | Quantitative systems pharmacology model: parameter values for a
Typical Patient.
Symbol Quantity Value
MODEL OF ATHEROSCLEROSIS
Rlumen (mm) Initial lumen radius 3.0
km (m
3 cells−1 s−1) Foam cell formation constant 9.25 × 10−24
dm (s
−1) Diffusion of monocytes out of the plaque 5.75 × 10−6
dlox (s
−1) Diffusion of LDL out of the plaque 2.4 × 10−5
dM (s
−1) Diffusion of macrophages out of the plaque 5.75 × 10−6
dF (s
−1) Diffusion of foam cells out of the plaque 5.75 × 10−6
rw (s
−1) LDL oxidation rate constant 3 × 10−4
µ (Pa s) Blood viscosity 0.004
ρ1 (s
−1) Rate of differentiation of monocytes 1.15 × 10−6
∆p (Pa) Endothelial pressure difference 2,400
Q(l/s) Blood flow 0.0075
mlumen (cells/l) Concentration of monocytes in blood 5.5 × 10
8
σ Endothelial reflection coefficient 0.997
PKPD MODEL
CL2(L/hr) Clearance compartment 2 1,740
V2(L) Volume compartment 2 8,980
CL3(L/hr) Clearance compartment 3 383
V3 (L) Volume compartment 3 1,190
Ka (1/hr) Absorption rate constant 2.76
Kin (nmol/L/hr) Production rate of LDL 29.52
Emax Max. effect due to the drug 0.489
EC50 (ng/mL) Blood concentration at half max. effect 0.0868
LDLbaseline (nmol/L) Baseline LDL 1,400
Computational Algorithm
The integration of the different (sub) models presented
previously is summarized in Figure 7. The aim of the complete
multiscale modeling framework is allowing the user to have
enough flexibility in the implementation in order to simulate
and test a variety of different case-scenarios, from simulating
patients with no treatment or non-adherent to their medication
(exploring only atherosclerotic plaque progression) to group of
patients with a given adherence and persistence (e.g., taking all
the prescribed drug or missing some of the doses in the whole
treatment).
RESULTS: A CASE STUDY
The multiscale model proposed here is the result of integrating
several approaches to capture and understand the progression
of atherosclerosis and how statins helps to inhibit plaque
development. The clinical endpoint is related to how the plaque
size changes dynamically. The fact that vascular remodeling
under these hypotheses is akin to a “positive feedback loop” with
nested/coupled processes, means that the dynamic behavior of
the plaque has an effect on all the components of this model,
mainly because changes in the arterial wall affect WSS and also
the concentration of biochemical species in the artery and the
lumen (see Figures 1, 2). The complete model is composed of
four main components which were coupled to describe all the
relevant mechanisms and interactions: (1) Mechanical properties
of the artery, including blood flow; (2) Macromolecule and
immune cell transport through the endothelium; (3) PK model
of statins (e.g., considering administration and metabolism
of the drug) and their pharmacological effect; (4) simulation
and analysis of adherence. Parameter values in the different
parts of the model can be modified in order to study the
variability of plaque growth in a given patient population.
Table 1 shows a summary of the physiological parameters used
in this model; more details can be found in Pichardo-Almarza
et al. (2014). Figure 8 shows how changes in some model
parameters (please see below) produce different dynamics for
plaque growth for a patient group. In particular, it is possible
to identify the individual time when the plaque starts to
grow.
Figure 9 shows the behavior of the model (i.e., rate of
plaque growth, measured in terms of volume) for an individual
patient without any treatment (control, blue line) vs. the
effect of the same patient on the drug (dotted red line).
Changes in the growing slope were previously compared
with the plaque growing trends obtained from Jensen et al.’s
study (Jensen et al., 2004) and already presented in Pichardo-
Almarza et al. (2014). Decreasing circulating LDL due to the
simvastatin therapy has an additional effect on decreasing
the transport of LDL through the arterial wall, which also
affects the production of foam cells, leading to a slower
plaque growth rate. Please note that the %TAV is the
change (%) of Total Atheroma Volume, calculated by the
model.
Furthermore, the model is helpful to explore how blood
flow has an effect on the initiation and progression of the
atherosclerotic plaque. The pattern of blood flow (and specific
properties as WSS Tricot et al., 2000) will be affected due
to changes in lumen diameter owing to plaque growth. Also
endothelial cells will respond to signals induced by changes
in WSS (Dimmeler et al., 1999; Tricot et al., 2000). Thus, the
shear stress regions of the atherosclerotic plaque will remain
atheroprone.
An example of the effect of medication adherence on the
progression of the atherosclerotic plaque is shown in Figure 10,
which demonstrates how, by using a discrete probabilistic
approach (Markov Chain) in the model, the user can compare
different scenarios between a control group, a regular group
(“adherents”) and a “less adherent” group (missing some doses
during implementation). In the example, adherent patients
are considered as patients taking all the doses during a year
(so the Markov Chain model for dosing is not required);
the “less adherent” patients correspond to a case where the
Markov Chain model (Figure 6) was used with pt = 90%
and qnt = 25%. These different scenarios allow evaluating
the influence of missing some daily doses on the overall
effect of a treatment prescribed for a year. Statins seems to
still have a similar effect on plaque progression when the
patient misses some of the doses, however it is clear that
the effect on reducing the plaque growth is less than in the
regular case.
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FIGURE 8 | Comparison of simulation results using different individual parameters in the original physical–based model of atherosclerosis. Different lines show the
results of individual patients’ trajectories (plaque growth for individual patients); the time when the plaque starts to growth (time for transition) can be different for
different individuals.
DISCUSSION
Results of the coupling between the different
mathematical approaches to describe the pharmacokinetics/
pharmacodynamics of statins and different atherogenic
mechanisms in the artery show how changes in different
parameters of the model, able to represent individual patient
trajectories, can be used to evaluate different scenarios to study
atherosclerotic plaque growth. Comparing the results with the
clinical endpoints reported by Jensen et al. (2004) shows how
this kind of systems models can be calibrated with clinical
data reproducing the dynamic response of plaque growth
for untreated patients and patients treated with simvastatin
(Pichardo-Almarza et al., 2014).
Themain aim of this work is to use an adaptable approach and
different formalisms to develop a model that provides enough
flexibility to the user in order to create different case scenarios to
test physiological and pharmacological hypotheses in the study
of atherosclerosis, the effect of statins on the progression of
the disease and the effect of patient adherence (with multiple
possible scenarios) to treatment for different patient trajectories.
One of the main advantages of this approach is the possibility to
expand or simplify the model according to different assumptions
or requirements, made by the user. The approach is modular (i.e.,
the model can be decomposed in different parts), which means
the user has the possibility tomodify (or improve) a givenmodule
related to a specific physiological/biological process in order to
improve simulation results for further analyses and/or validation.
Just to provide an example, even if the analyses reported in
this paper only show the effects of simvastatin, other cholesterol-
lowering drugs could also be considered using the same modeling
approach, just by changing the pharmacological properties of
the drug. In this case, the PK model could be substituted by
previous models published in literature, more specifically any of
the models proposed by Faltaos et al. (2006) or Vargo et al. (2014)
could be “plugged in” the multiscale computational framework
in order to study the effect of atorvastatin. These features make
this work suitable for software development.
Atherosclerosis and the effect of statins in humans have
been analyzed in the past using conventional pharmacokinetics
and pharmacodynamics (PKPD) modeling approaches (Kim
et al., 2011; Wright et al., 2011). In particular, Wright et al.
(2011) explored the influence of variable compliance, circadian
cholesterol production and simvastatin dosing time on the
reduction of low-density lipoprotein (LDL). This work mainly
showed the impact of medication adherence on the effect of
statins on decreasing LDL levels in blood, however, to our
knowledge there are no previous attempts where a multiscale
approach as the one proposed here has been used to include
models of downstream biology/physiology in order to study the
effect of these drugs on the disease development and progression
(i.e., atherosclerosis).
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FIGURE 9 | Comparison of simulation results using the original physical-based model of atherosclerosis (blue line) and the effect on plaque growth when a one-year
statin treatment is considered on the model (red line).
Our work shows that these models can be combined with
a multi-scale approach, expanding the biological/physiological
mechanisms and providing a better description of specific
pathways related to the disease, the PKPD properties of the drugs
and patient behavior with respect to medication adherence. A
quantitative systems pharmacology (QSP) approach was applied,
which combines PKPD modeling and physiological/disease
modeling based on fluid dynamics and mass transport, providing
a holistic computational approach to describe the dynamic
interaction between different elements in the artery, the plaque,
and the drug.
MODEL VALIDATION
Themultiscale QSPmodel proposed was validated using available
data related to changes in Total Atheroma Volume (%TAV) for
control groups and patients treated with statins. When modeling
patients without treatment, the model estimates a plaque growth
in the middle of the growing slopes reported for the control
groups in the ENCORE II (Lüscher et al., 2009) and ESTABLISH
(Okazaki et al., 2004) clinical trials (see Figure 11A). When
implementing a statin treatment in the QSP model, the change
in the plaque growth slope due to the pharmacological effect of
the drug match very well the changes reported by Jensen et al.
(2004; see Figure 11B). To the best of the author’s knowledge,
there are no additional clinical studies in the literature that
can be used to compare the effects of statin adherence on
atherosclerotic plaque progression, however, there is evidence
that missing doses during statin implementation has an impact
on LDL levels (Kazerooni et al., 2013; Chen et al., 2015), for
example in the study from Kazerooni et al. (2013) it was reported
that in a veteran population of more than five thousand patients,
there was on average a decrease of LDL levels of 37 mg/dl for
adherents and 18 mg/dl for non-adherents after 12 months of
treatment (see Figure 11C); the QSP model reproduces similar
differences in LDL for these two groups of patients when
comparing individuals with total adherence and a group of
patients with a low proportion of taken doses with respect to
the original prescription (i.e., around 50% of the prescription; see
Figure 11D). An additional advantage of the QSP model is the
possibility of seeing the variations (i.e., oscillations) in the LDL
time course due to missed doses (see Figure 11E), something that
is not reported in clinical or epidemiological studies. This clearly
shows that it will be more useful for future model development if
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FIGURE 10 | Medication adherence: Simulation results comparing the effect of taking statins on a regular basis and missing some doses according to the output of the
Markov Chain. The blue (solid) line shows the model when no drug is administered; the red dotted line shows the effect of one-year treatment with Statins (considering
the patient taking the drug regularly); the green line shows the effect of a patient under the same Statin treatment but missing ∼10% of the total number of doses.
the data coming from the clinic also includes information about
the implementation of the drug for each patient (e.g., missing
doses, etc.), a variable that is not normally recorded in clinical
studies of statins.
LIMITATIONS
It is important to highlight that the lack of available (clinical)
data for adherence to compare against constitutes a limitation
that needs to be acknowledged. The authors hope that as this
type of approaches grow, relevant and rich datasets can be
collected to underpin the crucial developments of this type of
technology. Regrettably, this is not the case right now but we are
hopeful that in the future, longitudinal and multiscale datasets
will be collected for adherence purposes. In fact, it can be argued
that novel approaches such as the one presented here where
the disease in question (and not a surrogate biomarker) is the
endpoint, can pave the way for future studies by making a strong
case for data collection in longitudinal and coherent datasets at
multiple scales.
Another limitation regards the atherosclerosis model
presented here. This model is obviously simplified;
atherosclerosis is a complex and multifactorial disease with
contributors at different levels of biological organization. In
particular, the genetic component was not included, which might
affect the results for one specific patient trajectory (an individual
patient). Additionally, the model does not currently consider
the pleiotropic effects of statins (but could consider it in the
case of an expanded model). All this been said, the results at
the population level should still be representative and in fact,
there is good agreement between the simulation results and the
published data of epidemiological studies on statins as described
above in the “Results” and “Model Validation” sections.
There is also a simplification in the hemodynamics of the
system, notably through the use of a Newtonian model for blood,
Poiseuille flow and “idealized” arterial conduits. The model only
considers drug effect on the early stages of atherosclerosis (LDL,
monocyte infiltration, foam cell formation, etc.) but additional
mechanisms could be included, depending on data availability.
Finally, more research is necessary to understand the
consequences in terms of patient adherence of side-effects,
lifestyle and the environment, especially for long term treatment.
This is clearly out of the scope of this paper but we recognize
that this might have a strong impact in the adherence regime
for individual patients. If this could be accounted for in a more
mechanistic fashion, it would provide a better understanding
of the weighing of different aspects (besides biology) that affect
whether or not a patient is likely to continue with their treatment
as prescribed and the effect this might have at the clinical
endpoint.
Despite these limitations, the work presented here is strongly
anchored in the state of the art and current knowledge in this area
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FIGURE 11 | Model validation. (A) Comparison of plaque growth simulated by the QSP model with trends reported by clinical trials [ENCORE II (Lüscher et al., 2009)
and ESTABLISH (Okazaki et al., 2004)]. (B) Comparison of the plaque growth simulated by the model with the change in plaque growth trend reported by Jensen
et al. (2004). (C) Changes in LDL levels for adherent and non-adherent patients after 12-month statin treatment reported by Kazerooni et al. (2013). (D) Changes in
LDL levels obtained from the QSP model for adherent and non-adherent patients. (E) Time course of LDL changes due to treatment for adherent and non-adherent
patients obtained from the QSP model simulations.
and we believe it provides a tool to help understand the overall
effect of patient-adherence in the case of statins.
CONCLUSIONS
Data from controlled clinical trials and observational studies
have been reporting low adherence to statin medication (Rash
et al., 2016). These studies have shown a continuous decline
of adherence to statin therapy after the first prescription with
∼50% patient treated stopping the use within the first year of
treatment (Lemstra et al., 2012). Developing computational tools
allowing to estimate the benefits associated with statin therapies
in combination with patient behavior might help to understand
the effect of adherence in clinical endpoints and the possibility to
test case scenarios for specific patient populations
The approach proposed in this work for modeling and
simulation in physiology and pharmacology requires the
integration of different mathematical techniques and formalisms
in order to capture the hybrid nature of the problems
and mechanisms related to cholesterol-lowering drugs and
cardiovascular diseases.
Continuous models based on differential equations
are particularly useful to describe the physics of chronic
diseases such as atherosclerosis. However, additional, discrete
events modelsare needed to provide a description of specific
physiological mechanisms, e.g., plaque growth.
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Here, a hybrid approach was used to understand the
evolution of atherosclerotic plaque in individualized simulations,
combining different mechanisms, and hypotheses related to
the effect of specific dosage regimes (e.g., daily dose) on
patients treated with statins. The detailed description of diverse
formalisms used helps to explain and understand different
scenarios where the interplay between medication adherence
and pharmacological intervention could have an influence on
treatment efficacy and disease progression.
The work proposed in this paper is modular and adaptable
in essence. One of the highlights of this approach is that it
allows targeted modifications (extensions or simplifications) of
specific parts of the model without affecting the implementation
of the whole, which is an interesting feature for software
development. This attribute was particularly useful to build
“virtual” populations in order to evaluate the predictive effect
of the model when compared with clinical trials (Pichardo-
Almarza et al., 2014). The proposed simulation framework allows
the possibility to design more complex simulation strategies
(e.g., Monte Carlo Simulations) with specific tasks in mind,
in order to test specific biological/physiological/pharmacological
hypotheses in the study of atherosclerosis. Finally, this work
can be of interest to the biological, pharmacological and the
medical community as it allows to test hypotheses and “what-if ”
scenarios related to drug administration, patient adherence and
atherosclerotic development in a comprehensive way. Although,
reporting on software testing is not within the scope of this paper,
the framework presented here is currently being evaluated by
clinical pharmacology groups in UCL and it will be the object of
future work.
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